Associated Papers
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M et al.
Nature, 2024
38589574 (PubMed )
Supplement: 41586_2024_7205_MOESM5_ESM.xlsx › Additional_Cell_Panel_Data
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
26860319 (PubMed )
Supplement: 12859_2016_935_MOESM2_ESM.xlsx › Table_S5
Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.
Nichols AC et al.
Bmc Pharmacology & Toxicology, 2014
25428177 (PubMed )
Supplement: 40360_2014_350_MOESM1_ESM.xlsx › Supp._Table_1
Select a paper to view details